COVIran Barakat

COVIran Barakat is an inactivated virus-based vaccine developed by Shifa Pharmed Industrial Group, a subsidiary of the Barkat Pharmaceutical Group, for the prevention of COVID-19. The vaccine is produced using the BIV1 strain of the SARS-CoV-2 virus, which is chemically inactivated (typically using beta-propiolactone) and adsorbed onto an aluminum hydroxide adjuvant. By presenting the entire killed virus to the immune system, the vaccine induces a broad immune response against multiple viral proteins, including the spike, envelope, and nucleocapsid proteins. It was the first COVID-19 vaccine developed in the Middle East to receive emergency use authorization, which was granted by the Iran Food and Drug Administration in June 2021.

Brand names

COVIran Barakat

Other names

BarekatBarakat vaccine